MENU

Henry Chi Hang Fung, MD, FRCPE

Henry Chi Hang Fung, MD, FRCPE

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Vice Chair, Hematology Programs

Director, Bone MarrowTransplant Program

Specialties

Treatment Philosophy

Cancer treatment and bone marrow transplant represent a journey for my patients and their families, and it’s my sincere privilege to be a part of this experience. I consider us all to be critical members of a cohesive team in making the right decisions to meet my patients’ treatment goals while maintaining quality of life.

Follow on Twitter: @henrychihangfu1

Education, Training & Credentials

Educational Background

  • Fellow, Hematology/Oncology, Queen Mary Hospital, Hong Kong University, Hong Kong
  • Clinical Fellow, Division of Hematology, Vancouver Hospital and Health, Science Center, British Columbia Cancer Control Agency, University of British Columbia, Canada, 1992-1994 
  • Resident, Hematology/Oncology, Queen Mary Hospital, Hong Kong University, 1991-1992
  • Resident, Internal Medicine, Queen Mary Hospital, Hong Kong University, 1988-1991 
  • MBChB, Medicine, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, 1987

Certifications

  • FRCPE, awarded by Royal College of Physicians, Edinburgh, 2001
  • MRCP (UK), awarded by Royal College of  Physicians, United Kingdom 1991

Memberships

  • American College of Physicians
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Society of Blood and Marrow Transplantation
  • Royal College of Physicians, Edinburgh, United Kingdom

Honors & Awards

  • Castle Connoly Medical American Top Doctor (Cancer, Hematology) 2014, 2015
  • Fellow, American College of Physicians,2014
Patient Stories

Doreen Siemienski

Lymphoma

Doreen Siemienski

Lymphoma

When Doreen E. Siemienski was diagnosed with Non-Hodgkin’s Lymphoma in October 2006 at the age of 53, she called Fox Chase Cancer Center because of its reputation for high-quality care. “I know someone who was and is still being treated at Fox Chase,” Doreen says. “She had so many positive comments about the facility that she called it her haven and home away from home.”

Research Profile

Research Interests

  • Allogeneic stem cell transplantation using alternative donors
  • Treatment and stem cell transplantation for multiple myeloma, lymphoma and leukemias, myelodysplasia, myeloproliferative disease and myelofibrosis
Publications

Selected Publications

Syed A. Abutalib, Kieron Dunleavy & Henry C. Fung: Primary Mediastinal B Cell Lymphoma. In Clinical Oncology (In Press).

Henry C Fung, Philip Pancari and Patricia Kropf. Primary Central Nervous System Lymphoma. In Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation. Edited by Dr. Syed A. Abutalib & Dr. Parameswaran Hari (In Press).

Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.: A Goy, M Berger, P Ford, T Feldman, A Mato, C Bejot and Henry C Fung - Leukemia & lymphoma, 2014/12. PubMed

Gastrointestinal Side Effects and Adequacy of Enteral Intake in Hematopoietic Stem Cell Transplant Patients: M Walrath, C Bacon, S Foley, HC Fung - Nutrition in Clinical Practice, 2014/9. PubMed

Anger, provider responses, and pain: Prospective analysis of stem cell transplant patients: JI Gerhart, V Sanchez Varela, JW Burns, SE Hobfoll, HC Fung; Health Psychology 34 (3), 197. PubMed

Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients: SE Hobfoll, JI Gerhart, AK Zalta, K Wells, J Maciejewski and Henry C Fung- Psycho‐Oncology, 2015.   PubMed

Evaluating Neutropenia Recovery in Patients Receiving Filgrastim on Day+ 5 Versus Day+ 10 Post Autologous Hematopoietic Stem Cell Transplant: LM DiGrazia, M Janusek, K Schultz, L Geswein, HC Fung; Journal of Oncology Pharmacy Practice (in press).

Peksa GD, Schultz K, Fung HC: Dosing Algorithm for Concomitant Administration of Sirolimus, Tacrolimus, and an Azole After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Oncology Pharmacy Practice.  2014 June 17: pii:1078155214539625. [Epub ahead of print]. PubMed

Christopherson KW 2nd, Frank R, Jagan S, Paganessi LA, Rizman A, Gezer S, Gregory SA, Fung HC: CD26 Protease Inhibition Improves Functional Response of Un-fractionated Mobilized Peripheral Blood Mononuclear Cells to CXCL12/SDF-1. Exp Hematol 2012 Nov;40(11):945-52.doi:10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27. PubMed

Tuncer HH, Gregory SA, Fung HC: High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapse after Allo-SCT in Multiple Myeloma: A Case Report. Bone Marrow Transplant Oct 2010. PubMed

 Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ: Phase II trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients with Non-Hodgkin’s Lymphoma. Journal of clinical Oncology 2008 Jan 1;26(1):90-5. Epub 2007 Nov 19. PubMed

Fung HC, Stif P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A:. Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma. Biol Blood Marrow Transplant 2007 May;13(5):594-600. Epub 2007 Mar 23. PubMed

Sahebi F, Spielberger R, Kogut NM, Fung HC, et al.:  Maintenance Thalidomide Following Single Cycle Autologous Peripheral Blood Stem Cell Transplant in Patients with Multiple Myeloma. Bone Marrow Transplantation 2006 May;37(9):825-9. PubMed

Henry C Fung MBchB, FRCPE, Sunita Nathan MD, John J Maciejewski MD, PhD: Induction Chemotherapy Before Autologous Stem Cell Transplantation for Patients with Symptomatic Plasma Cell Myeloma----does it matter? Clinical Pharmacology: Advances and Applications (2010).  PubMed

A.M. Jimenez, Henry C Fung and Kent Chistopherson II: Strategies for Improving Transplant Efficiency in the Context of Cellular Therapeutics.  Transfusion 2011 Nov; 51 Suppl 4: 125S-137S.  doi: 10.1111/j. 1537-2995.2001.03375.x.   PubMed